Team/Members of the group:

• Dr Anindya Mukhopadhya, Project Manager on EU project/Post-Doc
• Dr Dimitris Tsiapalis, Post-Doc
• Dr Niamh McNamee, Post-Doc
• Mariadelva Catalano, PhD student
• Sarai Martinez, PhD student
• Jessie Santoro, PhD student 
• Roisin Daly, PhD student
• Rawan Almasri, MSc student 

Close collaborators:

• Prof. Maeve Lowery/Dr Simon Barry TSJCI
• Dr David Hoey, Bioengineering, TCD
• Prof. John Crown, St. Vincent’s University Hospital, Dublin
• Prof. Carla Oliveira, University of Porto, Portugal
• Dr Clotilde Thery, Institut Curie, Paris, France
• Prof. Edit Buzas, Semmelweis University, Hungary
• Prof. Marca Wauben, Utrecht University, The Netherlands
• Prof. An Hendrix, Ghent University, Belgium
• Prof. Irina Nazarenko, Freiburg University, Germany
• Prof. Bernd Giebel, Essen University Hospital, Germany

Main Funders:
EU Commission H2020, Irish Research Council (Advanced Laureate Award and individual Post-Graduate awards), Enterprise Ireland, Irish Cancer Society, DAFM, Health Research Board, Breast Cancer Now, industry 

Active research programmes: 
Professor O Driscoll’s research group draws on academic and industry experience relating to diagnostic biomarkers and companion diagnostics for predicting patients’ response to treatment, for evaluating new drugs and new drug combinations, and re-purposing old drugs for use in cancer treatment. The group work on understanding how drug-resistance, metastasis and immune suppression occur and so might be prevented. We are very interested in advanced/metastatic cancers, as well as early disease. They have niche expertise in exosomes and other extracellular vehicles (EVs) and their DNA, RNA, and protein cargo. On a number of occasions, we have translated our bench discoveries to clinical trials. 

Additional Information:
Substantial experience of work for industry to translate research for patient benefit. Very interesting in expanding this further.